Pharma Stocks

Nifty Pharma eyes breakout; Biocon, 2 others may rally up to 22%: Analyst

Kunal Shah of Mirae Asset ShareKhan expects breakout on the Nifty Pharma index above 23,500 levels; the analyst recommends Lupin, Biocon and Torrent Pharma as top sectoral stock bets.

Axis Sec sees upside in pharma, hospitals; Lupin, Aurobindo among top bets

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution

Blue Jet Healthcare tanks 19% in 2 days; nears issue price; here's why

The company said decrease in revenue from operations during Q3FY26 is due to lower sales of PI and Artificial Sweeteners.

Dr Reddy's: 5 technical reasons why Choice Broking is bullish on this stock

Analysts at Choice Broking expects Dr Reddy's Laboratories stock to gain up to 15.5%, and test ₹1,465 levels on the upside in the medium-term given the favourable structure on the weekly chart.

Divi's Labs shares fall 3% on Q3 earnings miss; brokerages split on outlook

Divi's Laboratories reported a consolidated profit after tax (PAT) of ₹583 crore, marginally lower than ₹589 crore in the same period last year

Alembic Pharma shares slide 4% on Q3 profit miss; is it a good time to buy?

Alembic Pharma shares today: Analysts at Motilal Oswal Financial Services (MOFSL) have retained their Neutral rating on Alembic Pharma, with a target price of ₹860 per share

New product launches to keep growth momentum healthy for Sun Pharma

Strong Q3 performance and a steady pipeline of new launches are expected to support Sun Pharma's growth outlook, with brokerages upgrading the stock

Aurobindo Pharma soars 6% on huge volumes; here's what triggered the rally

Aurobindo Pharma stock up on Friday: The government has imposed a Minimum Import Price fixed at ₹2,216/kg for Penicillin G and is expected to provide a significant benefit to the company.

Piramal Pharma shares gain 4% on Q3 results; check key highlights inside

Following the results announcement, the company's share price rose 3.78 per cent to log an intraday high of ₹159.79 per share

Sun Pharma Q3 Preview: Profit, revenue and key factors to watch in Dec qtr

Sun Pharma's net profit is expected to come at ₹3,040 crore, marking a decline of 5.6 per cent Y-o-Y, as against ₹3,220 crore in the year-ago period

Indian CRDMO market to outpace APAC; HDFC Sec starts coverage on top firms

While HDFC Securities has assigned a 'Buy' rating to Divi's Labs, Sai Life Sciences, and Piramal Pharma, it has given an 'Add' rating to Anthem BioSciences and a 'Reduce' rating to Laurus Labs

Gland Pharma rises 5%, hits 1-month high on USFDA nod to eye-allergy drug

Gland Pharma jumped 4.80 per cent to ₹1,790.40, the highest level since December 3, 2025, on the National Stock Exchange.

Indian pharma cos' new drug filings decline to 20-year low, Nomura says

Abbreviated new drug application filings have declined to 600 in the financial year 2025 (ending in September) versus 740 in the preceding year, Nomura said

Antique maintains 'Buy' on Concord Biotech; sees strong API, CDMO growth

Antique expects the Concord to report revenue, Ebitda and PAT CAGR of 18 per cent, 17 per cent and 19 per cent, respectively, with margins remaining stable at around 42 per cent over FY25-28E

Laurus zooms 82% so far in 2025; set for best yearly performance in 5 years

The stock hit a new high of ₹1,095, appreciated 117% from its 52-week low of ₹504.30 touched on January 28, 2025.

Ajanta Pharma shares up 3% as Biocon tie-up fuels long-term growth optimism

Ajanta Pharma shares gained 3% despite a weak market as analysts turned bullish on its Biocon partnership, semaglutide opportunity, and growth outlook

Ajanta Pharma hits over 5-month high after partnering with Biocon

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market Semaglutide

Why did Emcure Pharma share price rise 2% in overall muted market?

At 9:25 AM, Emcure Pharma share price continued to trade 1 per cent higher at ₹1,392, even as BSE Sensex trade flat with a negative bias at 85,509.78 levels.

Why did Sudeep Pharma plunge 6% in trade today? Key details inside

Sudeep Pharma share price fell on reporting a weak set of results in the September quarter of financial year 2026 (Q2FY26).

Sharekhan upgrades Divi's Labs to 'Buy' on strong FY26-28 growth visibility

The brokerage said Divis Laboratories is entering a stronger growth phase, supported by a robust H2FY26 pipeline and visibility for scale-up over the next two years.